JP2020519672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519672A5 JP2020519672A5 JP2019563217A JP2019563217A JP2020519672A5 JP 2020519672 A5 JP2020519672 A5 JP 2020519672A5 JP 2019563217 A JP2019563217 A JP 2019563217A JP 2019563217 A JP2019563217 A JP 2019563217A JP 2020519672 A5 JP2020519672 A5 JP 2020519672A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- inhibitor
- ret
- combination according
- mtorc1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- GBLBJPZSROAGMF-RWYJCYHVSA-N C[C@@H](c(cc1)cnc1-[n]1ncc(F)c1)NC([C@](CC1)(CC[C@@H]1c1nc(Nc2n[nH]c(C)c2)cc(C)n1)OC)=O Chemical compound C[C@@H](c(cc1)cnc1-[n]1ncc(F)c1)NC([C@](CC1)(CC[C@@H]1c1nc(Nc2n[nH]c(C)c2)cc(C)n1)OC)=O GBLBJPZSROAGMF-RWYJCYHVSA-N 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506334P | 2017-05-15 | 2017-05-15 | |
| US62/506,334 | 2017-05-15 | ||
| US201862652284P | 2018-04-03 | 2018-04-03 | |
| US62/652,284 | 2018-04-03 | ||
| US201862656297P | 2018-04-11 | 2018-04-11 | |
| US62/656,297 | 2018-04-11 | ||
| US201862657605P | 2018-04-13 | 2018-04-13 | |
| US62/657,605 | 2018-04-13 | ||
| PCT/US2018/032794 WO2018213329A1 (en) | 2017-05-15 | 2018-05-15 | Combinations of ret inhibitors and mtorc1 inhibitors and uses thereof for the treatment of cancer mediated by aberrant ret activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020519672A JP2020519672A (ja) | 2020-07-02 |
| JP2020519672A5 true JP2020519672A5 (enExample) | 2021-07-26 |
Family
ID=62567777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563217A Withdrawn JP2020519672A (ja) | 2017-05-15 | 2018-05-15 | ＲＥＴ阻害剤とｍＴＯＲＣ１阻害剤との組合せ及び異常なＲＥＴ活性によって媒介されるがんを処置するためのその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210290620A1 (enExample) |
| EP (1) | EP3624802A1 (enExample) |
| JP (1) | JP2020519672A (enExample) |
| CN (1) | CN110891573A (enExample) |
| WO (1) | WO2018213329A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| EA038890B1 (ru) | 2015-11-02 | 2021-11-03 | Блюпринт Медсинс Корпорейшн | Ингибиторы ret |
| CA3096043A1 (en) | 2018-04-03 | 2019-10-10 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
| CN111961034A (zh) * | 2019-05-20 | 2020-11-20 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
| JP2023501757A (ja) * | 2020-05-29 | 2023-01-18 | ブループリント メディシンズ コーポレイション | プラルセチニブ薬学的組成物 |
| KR20230017234A (ko) | 2020-05-29 | 2023-02-03 | 블루프린트 메디신즈 코포레이션 | 프랄세티닙의 고체 형태 |
| CN116867492A (zh) * | 2020-11-20 | 2023-10-10 | 赫尔森保健股份公司 | 使用4-氨基-n-[4-(甲氧基甲基)苯基]-7-(1-甲基环丙基)-6-(3-吗啉代丙-1-炔-1-基)-7h-吡咯并[2,3-d]嘧啶-5-羧酰胺治疗肿瘤的方法 |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100047777A1 (en) | 2005-05-26 | 2010-02-25 | The Johns Hopkins University | Methods for identifying mutations in coding and non-coding dna |
| WO2009003136A1 (en) * | 2007-06-26 | 2008-12-31 | Rigel Pharmaceuticals, Inc. | Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders |
| WO2009100536A1 (en) | 2008-02-15 | 2009-08-20 | Methylgene Inc. | Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures |
| EP2740742B1 (en) | 2011-08-04 | 2018-03-14 | National Cancer Center | Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene |
| WO2013028817A1 (en) | 2011-08-23 | 2013-02-28 | Foundation Medicine , Inc. | Novel kif5b-ret fusion molecules and uses thereof |
| US20130096136A1 (en) | 2011-09-30 | 2013-04-18 | Methylgene Inc. | Inhibitors of Protein Tyrosine Kinase Activity |
| JP2015109806A (ja) | 2012-03-22 | 2015-06-18 | アステラス製薬株式会社 | 新規ｒｅｔ融合体の検出法 |
| AU2013259267A1 (en) * | 2012-05-10 | 2014-11-06 | Synta Pharmaceuticals Corp. | Treating cancer with Hsp90 inhibitory compounds |
| JPWO2014017491A1 (ja) | 2012-07-26 | 2016-07-11 | 国立研究開発法人国立がん研究センター | Ｃｅｐ５５遺伝子とｒｅｔ遺伝子との融合遺伝子 |
| SG11201502211QA (en) | 2012-09-25 | 2015-05-28 | Chugai Pharmaceutical Co Ltd | Ret inhibitor |
| PE20151538A1 (es) | 2013-03-15 | 2015-11-18 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret) |
| WO2015006875A1 (en) | 2013-07-18 | 2015-01-22 | Methylgene Inc. | Process for the preparation of substituted pyrimidines |
| US20150057335A1 (en) | 2013-08-20 | 2015-02-26 | National Cancer Center | Novel fusion genes identified in lung cancer |
| GB201321146D0 (en) | 2013-11-29 | 2014-01-15 | Cancer Rec Tech Ltd | Quinazoline compounds |
| US9879021B2 (en) | 2014-09-10 | 2018-01-30 | Glaxosmithkline Intellectual Property Development Limited | Compounds as rearranged during transfection (RET) inhibitors |
| PL3191450T3 (pl) | 2014-09-10 | 2019-08-30 | Glaxosmithkline Intellectual Property Development Limited | Pochodne pirydonu jako inhibitory kinazy rearanżowanej podczas transfekcji (ret) |
| CA2967125C (en) | 2014-11-14 | 2022-10-25 | Nerviano Medical Sciences S.R.L. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| DK3322706T3 (da) | 2015-07-16 | 2021-02-01 | Array Biopharma Inc | Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer |
| CN105255927B (zh) | 2015-09-30 | 2018-07-27 | 温州医科大学附属第一医院 | 一种kiaa1217-ret融合基因 |
| EA038890B1 (ru) | 2015-11-02 | 2021-11-03 | Блюпринт Медсинс Корпорейшн | Ингибиторы ret |
| AR107912A1 (es) | 2016-03-17 | 2018-06-28 | Blueprint Medicines Corp | Inhibidores de ret |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
-
2018
- 2018-05-15 WO PCT/US2018/032794 patent/WO2018213329A1/en not_active Ceased
- 2018-05-15 US US16/613,625 patent/US20210290620A1/en not_active Abandoned
- 2018-05-15 EP EP18730519.8A patent/EP3624802A1/en not_active Withdrawn
- 2018-05-15 JP JP2019563217A patent/JP2020519672A/ja not_active Withdrawn
- 2018-05-15 CN CN201880046867.7A patent/CN110891573A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020519672A5 (enExample) | ||
| US20230218655A1 (en) | Cancer treatments | |
| JP2021520349A5 (enExample) | ||
| Brunen et al. | TGF-β: an emerging player in drug resistance | |
| US20210100825A1 (en) | Cancer treatments based on gemcitabine prodrugs | |
| JP2020514292A5 (enExample) | ||
| JP2020527139A5 (enExample) | ||
| JP2017514806A5 (enExample) | ||
| CN101332301A (zh) | 一种抗肿瘤组合物及其应用 | |
| Mir et al. | Introduction to breast cancer | |
| Butt et al. | BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series | |
| Roldán et al. | A primary signet ring cell carcinoma of the prostate with bone metastasis with impressive response to FOLFOX and cetuximab | |
| Gao et al. | Wild-type KRAS and BRAF could predict response to cetuximab in Chinese colorectal cancer patients | |
| Melichar et al. | Pathological complete response in advanced gastrointestinal stromal tumor after imatinib therapy | |
| TW201803566A (zh) | 用於癌症治療之維持療法 | |
| Alzarkali et al. | Ipilimumab and nivolumab after disease progression on single agent immunotherapy in mismatch repair deficient metastatic colorectal cancer. | |
| RU2020135917A (ru) | Ингибитор ret для применения в лечении рака, имеющего ret-альтерацию | |
| JPWO2021108682A5 (enExample) | ||
| Rivera et al. | Adjuvant radiotherapy for rectal cancer: recent results, new questions | |
| Wang et al. | The efficacy of olaparib as salvage therapy in an advanced intrahepatic cholangiocarcinoma patient harboring somatic BRCA1 and PALB2 pathogenic variants: a case report and literature review | |
| Ohashi et al. | Gastrojejunostomy as induction treatment for S-1-based chemotherapy in patients with incurable gastric cancer | |
| Toullec et al. | 225 oxidative stress promotes myofibroblast differentiation and tumour spreading | |
| RU2021131604A (ru) | Соединения с противоопухолевой активностью против раковых клеток, несущих инсерции в экзоне 21 her2 | |
| Tycko et al. | 224 Epigenetics of carcinoma-associated myofibroblasts: implications for anti-cancer therapies | |
| Hayashida et al. | 226 HOXB9, a gene overexpressed in breast cancer, induces angiogenesis, invasion, and lung metastasis |